Compare Ginkgo Bioworks Holdings Inc (DNA) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Under Armour Inc Class A — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.72 (market cap $763.64M), while Under Armour Inc Class A trades at $4.9 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 2.7× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Under Armour Inc Class A for 99 Days on average.
| DNA | UAA | |
|---|---|---|
Market Cap | $763.64M | $2.07B |
Volume | 3,204,177 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $8.14 |
52-Week Low | $5.48 | $4.17 |
Typical Hold Time | 7 Days | 99 Days |
Enterprise Value | $865.59M | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Under Armour (UAA) trades at $4.82, down 1.23% on the day, with a mixed technical picture showing a bullish overall signal but a neutral RSI. The company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. Analyst consensus is a $5.79 price target, but the stock faces headwinds from weak consumer demand and negative cash flow trends.
The outlook is cautious; while cost discipline supports margins, persistent revenue weakness and negative profitability pose significant risks. The stock's low P/S ratio of 0.42 may attract value investors, but sustained operational improvements are needed for a durable recovery amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
